3 results
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMORecruiting
Main: - To evaluate the effect of efavaleukin alfa on induction of clinical remissionSecondary: - To evaluate the effect of efavaleukin alfa on induction of clinical response- To evaluate the effect of efavaleukin alfa on induction of endoscopic…
Approved WMORecruiting
To evaluate the potential effect of PPI administration in women with confirmed preeclampsia on sFlt-1 levels until delivery.